However, emerging evidence suggests that PD-1 blockade may reshape the tumor immune microenvironment (TIME) in recurrent GBM, potentially reinvigorating antitumor immune responses at both local and systemic levels and enhancing the infiltration of immune cells into the tumor [5,6]. The gene discussed is PDCD1; the disease is glioblastoma.